Therapy for early-stage colorectal cancer

M. Peeters, D. G. Haller, Steven Robert Alberts, R. M. Goldberg, R. Smith

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Surgery is the only curative option for patients with colorectal cancer. The goal of other modalities, such as chemotherapy, immunotherapy, and radiotherapy, is to prolong survival and reduce the risk of recurrence. Adjuvant treatment is mandatory for patients with stage III colon cancer. At present, 6 months of fluorouracil (5-FU) plus leucovorin (folinic acid) can be considered standard therapy. The data on stage II colon cancer are less convincing, and perhaps only subgroups benefit from adjuvant therapy. Patients with stage II disease should be encouraged to participate in randomized trials. Outside of such trials, one can consider prognostic factors in the decision to offer adjuvant therapy. Patients with T3 or N1-3 M0 rectal cancer should receive combined-modality therapy, ie, 5-FU-based chemotherapy and irradiation. Until ongoing trials answer the question of whether a patient should be irradiated preoperatively or postoperatively, the type of surgery determines the timing of irradiation. If the tumor is amenable to a sphincter-preserving operation, surgery can be followed by radiation therapy. In patients with fixed tumors and those in whom resectability is an issue, prolonged preoperative radiotherapy is more appropriate. Ongoing trials should optimize existing adjuvant therapy (by achieving an ideal balance between toxicity and effectiveness) and integrate the advantages of recently approved drugs.

Original languageEnglish (US)
Pages (from-to)307-321
Number of pages15
JournalOncology
Volume13
Issue number3
StatePublished - 1999
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Radiotherapy
Leucovorin
Fluorouracil
Colonic Neoplasms
Therapeutics
Drug Therapy
Combined Modality Therapy
Rectal Neoplasms
Immunotherapy
Neoplasms
Recurrence
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Peeters, M., Haller, D. G., Alberts, S. R., Goldberg, R. M., & Smith, R. (1999). Therapy for early-stage colorectal cancer. Oncology, 13(3), 307-321.

Therapy for early-stage colorectal cancer. / Peeters, M.; Haller, D. G.; Alberts, Steven Robert; Goldberg, R. M.; Smith, R.

In: Oncology, Vol. 13, No. 3, 1999, p. 307-321.

Research output: Contribution to journalArticle

Peeters, M, Haller, DG, Alberts, SR, Goldberg, RM & Smith, R 1999, 'Therapy for early-stage colorectal cancer', Oncology, vol. 13, no. 3, pp. 307-321.
Peeters M, Haller DG, Alberts SR, Goldberg RM, Smith R. Therapy for early-stage colorectal cancer. Oncology. 1999;13(3):307-321.
Peeters, M. ; Haller, D. G. ; Alberts, Steven Robert ; Goldberg, R. M. ; Smith, R. / Therapy for early-stage colorectal cancer. In: Oncology. 1999 ; Vol. 13, No. 3. pp. 307-321.
@article{bebebf3e739c49e4bb1e4599b2a1b9a2,
title = "Therapy for early-stage colorectal cancer",
abstract = "Surgery is the only curative option for patients with colorectal cancer. The goal of other modalities, such as chemotherapy, immunotherapy, and radiotherapy, is to prolong survival and reduce the risk of recurrence. Adjuvant treatment is mandatory for patients with stage III colon cancer. At present, 6 months of fluorouracil (5-FU) plus leucovorin (folinic acid) can be considered standard therapy. The data on stage II colon cancer are less convincing, and perhaps only subgroups benefit from adjuvant therapy. Patients with stage II disease should be encouraged to participate in randomized trials. Outside of such trials, one can consider prognostic factors in the decision to offer adjuvant therapy. Patients with T3 or N1-3 M0 rectal cancer should receive combined-modality therapy, ie, 5-FU-based chemotherapy and irradiation. Until ongoing trials answer the question of whether a patient should be irradiated preoperatively or postoperatively, the type of surgery determines the timing of irradiation. If the tumor is amenable to a sphincter-preserving operation, surgery can be followed by radiation therapy. In patients with fixed tumors and those in whom resectability is an issue, prolonged preoperative radiotherapy is more appropriate. Ongoing trials should optimize existing adjuvant therapy (by achieving an ideal balance between toxicity and effectiveness) and integrate the advantages of recently approved drugs.",
author = "M. Peeters and Haller, {D. G.} and Alberts, {Steven Robert} and Goldberg, {R. M.} and R. Smith",
year = "1999",
language = "English (US)",
volume = "13",
pages = "307--321",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Therapy for early-stage colorectal cancer

AU - Peeters, M.

AU - Haller, D. G.

AU - Alberts, Steven Robert

AU - Goldberg, R. M.

AU - Smith, R.

PY - 1999

Y1 - 1999

N2 - Surgery is the only curative option for patients with colorectal cancer. The goal of other modalities, such as chemotherapy, immunotherapy, and radiotherapy, is to prolong survival and reduce the risk of recurrence. Adjuvant treatment is mandatory for patients with stage III colon cancer. At present, 6 months of fluorouracil (5-FU) plus leucovorin (folinic acid) can be considered standard therapy. The data on stage II colon cancer are less convincing, and perhaps only subgroups benefit from adjuvant therapy. Patients with stage II disease should be encouraged to participate in randomized trials. Outside of such trials, one can consider prognostic factors in the decision to offer adjuvant therapy. Patients with T3 or N1-3 M0 rectal cancer should receive combined-modality therapy, ie, 5-FU-based chemotherapy and irradiation. Until ongoing trials answer the question of whether a patient should be irradiated preoperatively or postoperatively, the type of surgery determines the timing of irradiation. If the tumor is amenable to a sphincter-preserving operation, surgery can be followed by radiation therapy. In patients with fixed tumors and those in whom resectability is an issue, prolonged preoperative radiotherapy is more appropriate. Ongoing trials should optimize existing adjuvant therapy (by achieving an ideal balance between toxicity and effectiveness) and integrate the advantages of recently approved drugs.

AB - Surgery is the only curative option for patients with colorectal cancer. The goal of other modalities, such as chemotherapy, immunotherapy, and radiotherapy, is to prolong survival and reduce the risk of recurrence. Adjuvant treatment is mandatory for patients with stage III colon cancer. At present, 6 months of fluorouracil (5-FU) plus leucovorin (folinic acid) can be considered standard therapy. The data on stage II colon cancer are less convincing, and perhaps only subgroups benefit from adjuvant therapy. Patients with stage II disease should be encouraged to participate in randomized trials. Outside of such trials, one can consider prognostic factors in the decision to offer adjuvant therapy. Patients with T3 or N1-3 M0 rectal cancer should receive combined-modality therapy, ie, 5-FU-based chemotherapy and irradiation. Until ongoing trials answer the question of whether a patient should be irradiated preoperatively or postoperatively, the type of surgery determines the timing of irradiation. If the tumor is amenable to a sphincter-preserving operation, surgery can be followed by radiation therapy. In patients with fixed tumors and those in whom resectability is an issue, prolonged preoperative radiotherapy is more appropriate. Ongoing trials should optimize existing adjuvant therapy (by achieving an ideal balance between toxicity and effectiveness) and integrate the advantages of recently approved drugs.

UR - http://www.scopus.com/inward/record.url?scp=0032963179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032963179&partnerID=8YFLogxK

M3 - Article

C2 - 10204153

AN - SCOPUS:0032963179

VL - 13

SP - 307

EP - 321

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -